Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($0.54), $0.02 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.